8-K: Vivos Therapeutics Reports Q1 2024 Results, Highlights Cost Reductions and Medicare Approval

Vivos Therapeutics announced its first quarter 2024 financial results, showcasing reduced operating expenses and progress in expanding product offerings and regulatory approvals, including Medicare reimbursement for its CARE oral devices.

Summary

• Vivos Therapeutics reported a revenue of $3.4 million for the first quarter of 2024, a decrease from $3.8 million in the same period of 2023, primarily due to lower VIP enrollments and CARE appliance revenue.
• This revenue decrease was partially offset by increased sales of Vivos Pediatric and Lifeline appliances and home sleep testing services.
• The company's gross profit was $1.9 million, down from $2.3 million in Q1 2023, with a gross margin of 57% compared to 61% in the prior year.
• Operating expenses saw a significant reduction of 22%, or $1.6 million, compared to the first quarter of 2023, marking the seventh consecutive quarter of year-over-year improvement.
• This cost-cutting led to a 24% reduction in operating loss, which was $1.2 million lower than the first quarter of 2023.
• Vivos anticipates achieving positive cash flow operations by the end of 2024 or during the first quarter of 2025, assuming revenue increases as planned.
• In February 2024, a warrant exercise generated gross proceeds of approximately $4.0 million.
• As of March 31, 2024, Vivos had $2.6 million in cash and cash equivalents.
• The company has treated over 42,600 patients worldwide and trained more than 1,950 dentists in the use of The Vivos Method.
• In April 2024, Vivos received Medicare reimbursement approval for its CARE oral devices, potentially expanding access to millions of beneficiaries.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant cost reductions and Medicare approval, but tempered by a revenue decline and the need for further growth initiatives.

Positives

• Vivos has successfully reduced operating expenses for seven consecutive quarters.
• The company has expanded its product offerings, including Pediatric and Lifeline appliances.
• Vivos has obtained Medicare reimbursement for its CARE oral devices, opening up a significant market opportunity.
• The number of patients treated with Vivos devices has increased to over 42,600.
• The company has trained more than 1,950 dentists in the use of The Vivos Method.
• Vivos is anticipating positive cash flow operations by the end of 2024 or during the first quarter of 2025.

Negatives

• Revenue decreased to $3.4 million in Q1 2024 from $3.8 million in Q1 2023.
• Gross profit decreased to $1.9 million in Q1 2024 from $2.3 million in Q1 2023.
• Gross margin decreased to 57% in Q1 2024 from 61% in Q1 2023.
• The company experienced lower VIP enrollments and CARE appliance revenue.

Risks

• Vivos may not be able to generate additional revenue from Medicare reimbursement or other strategies.
• Some patients may not achieve the desired results from using Vivos products.
• The company faces risks associated with regulatory scrutiny and adverse publicity in the sleep apnea treatment sector.
• Vivos may be unable to secure additional financing on reasonable terms or maintain its Nasdaq listing.
• The company's revenue is still reliant on VIP enrollments, despite efforts to diversify.

Future Outlook

Vivos anticipates achieving positive cash flow operations by the end of 2024 or during the first quarter of 2025, assuming revenue increases as planned. The company also expects increased demand for its products due to market shifts and regulatory approvals.

Management Comments

• Kirk Huntsman, Vivos Chairman and CEO, stated that they are proud of their cost management and efforts to expand product offerings and gain regulatory approvals.
• Mr. Huntsman also acknowledged that revenues have not grown as desired and announced a new strategic revenue initiative based on collaborations with referring medical professionals.
• Management believes the Medicare reimbursement approval has the potential to drive increased patient count and utilization of Vivos devices and methods.
• Management is positive about the company's prospects for the rest of this year and into 2025.

Industry Context

The announcement comes at a time when the sleep apnea treatment market is experiencing shifts, including Phillips Respironics suspending CPAP shipments and United Healthcare mandating oral appliance therapy before neurostimulation implants. These changes are expected to increase demand for Vivos' products and services.

Comparison to Industry Standards

• While Vivos has shown progress in cost reduction, its revenue decline contrasts with the growth seen by some competitors in the sleep apnea device market, such as ResMed, which has reported consistent revenue growth.
• The Medicare reimbursement approval for Vivos' CARE devices is a significant step, potentially placing them in a more competitive position against companies like SomnoMed, which also offers oral appliance therapy.
• Vivos' focus on a non-surgical approach aligns with a growing trend towards less invasive treatments, but they need to demonstrate stronger revenue growth to compete effectively with established players in the market.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by cost reductions and the Medicare approval.
• Employees may be affected by cost-cutting measures, but the company's growth prospects could provide job security.
• Customers (patients) will benefit from increased access to Vivos' products through Medicare reimbursement.
• Dentists will have more opportunities to offer Vivos' treatments to their patients.
• Suppliers may see increased demand for Vivos' products.

Next Steps

• Vivos plans to launch a new strategic revenue initiative based on collaborations with referring medical professionals.
• The company will provide additional details on its investor call and in the coming weeks.
• Vivos will continue to focus on expanding its product line and revenue potential.
• The company will continue to work on its durable medical equipment and other sales and marketing efforts.
• Vivos will continue to develop additional programs for dentists to enroll with Vivos.

Key Dates

Keywords

Vivos Therapeutics, Sleep Apnea, Oral Appliances, Medicare Reimbursement, Medical Devices, Financial Results, Cost Reduction, Revenue Growth, Operating Expenses, Healthcare